Mustang Bio Inc.

Iovance Biotherapeutics, Inc. ’s tumor-infiltrating lymphocyte (TIL) Amtagvi (lifileucel) scored a win in February as the first cell therapy to win US Food and Drug Administration approval for a solid

Cullinan Oncology, Inc. is changing course and increasing its focus on inflammation and immunology. The company will rebrand as Cullinan Therapeutics, Inc. as it moves CLN-978, its CD19xCD3-directed

Mustang Bio Inc. is following an increasing portion of the CAR-T cell therapy field in expanding development of its lead product candidate, MB-106, to include autoimmune diseases in addition to the B

Two of the reasons why glioblastoma multiforme (GBM) has proven one of the toughest cancers in oncology – being incurable, invariably fatal and with a median overall survival (OS) of two years or less